Sagent Pharma Announces Launch Of Colistimethate For Injection

(RTTNews) - Sagent Pharmaceuticals Inc (SGNT) said it has launched Colistimethate for Injection, USP, an anti-infective, in a preservative-free glass vial.

Colistimethate for injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.

According to IMS, for the 12 months ending October 2014, the U.S. market for Colistimethate totaled $12 million. Sagent said that as with all products in its portfolio, Colistimethate features the company's PreventIV Measures packaging and labeling, designed to help reduce medication errors.